Immutep : SITC 2022 - TACTI-002 Poster

(marketscreener.com) Combining the antigen-presenting cell activator eftilagimod alpha and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 Abstract # 1470 Iams W1; Felip E2;...https://www.marketscreener.com/quote/stock/IMMUTEP-LIMITED-38892320/news/Immutep-SITC-2022-TACTI-002-Poster-42273344/?utm_medium=RSS&utm_content=20221110